TET 101
Alternative Names: TET-101Latest Information Update: 19 Jul 2024
At a glance
- Originator Tetraneuron
- Class Antidementias; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 26 Jun 2024 Tetraneuron files for worldwide patent protection under PCT for “Phosphorylation on the Thr-248 and/or Thr-250 residues of transcription factor E2F4 as a therapeutic target in pathological processes associated with somatic polyploidy”
- 26 Jun 2024 Tetraneuron has patent protection for “Phosphorylation on the Thr-248 and/or Thr-250 residues of transcription factor E2F4 as a therapeutic target in pathological processes associated with somatic polyploidy” in Spain, USA, Europe and Japan
- 26 Jun 2024 Preclinical trials in Alzheimer's disease in Spain (Parenteral) before June 2024 (Tetraneuron pipeline, June 2024)